We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 21 for:    Copanlisib
Previous Study | Return to List | Next Study

Copanlisib in Association With Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas Harboring a PI3KCA Mutation/Amplification and/or a PTEN Loss (COPAN-ORL06)

This study is currently recruiting participants.
Verified March 2017 by UNICANCER
Sponsor:
ClinicalTrials.gov Identifier:
NCT02822482
First Posted: July 4, 2016
Last Update Posted: March 30, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
UNICANCER
  Purpose

The study consists of two distinct and sequential parts:

  • A Phase Ib aimed at determining the MTD (Maximum Tolerated Dose) of the combination (copanlisib/cetuximab) and the RP2D
  • A Phase II aimed at evaluating the efficacy of the combination at the RP2D (Recommended Phase 2 Dose)

All patients will be treated with the Copanlisib, a selective PI3KCA inhibitor, in association with Cetuximab.


Condition Intervention Phase
Carcinoma, Squamous Cell of Head and Neck Drug: Copanlisib Drug: Cetuximab Phase 1 Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase ib/II Trial of Copanlisib, a Selective PI3K Inhibitor, in Combination With Cetuximab in Patients With Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) Harboring a PI3KCA Mutation/Amplification and/or a PTEN Loss.

Resource links provided by NLM:


Further study details as provided by UNICANCER:

Primary Outcome Measures:
  • Phase Ib (dose escalation phase): to determine the Maximal Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) of Copanlisib in association with Cetuximab [ Time Frame: 1 month ]
    Determination of the MTD will be based on the occurence of Dose Limiting Toxicities during Cycle 1.

  • Phase II (expansion phase) : to assess the efficacy of the combination (Copanlisib + Cetuximab) at the RP2D. [ Time Frame: 16 weeks ]
    Efficacy of the combination will be assessed through Progression Free Survival at week 16.


Secondary Outcome Measures:
  • Efficacy of the combination [ Time Frame: Through the study completion with an average of 10 months ]
    Objective Response Rate (ORR) using RECIST 1.1 criteria

  • Efficacy of the combination [ Time Frame: Through the study completion with an average of 10 months ]
    Overall Survival (OS)

  • Adverse Events (NCI CTCAE v4.0) [ Time Frame: Up to 15 cycles ]
    All Adverse Events (NCI CTCAE v4.0), related or not related to Copanlisib or Cetuximab, will be collected in the Case Report Form in order to picture the safety profile of the association.

  • Copanlisib Maximum Plasma Concentration [Cmax] [ Time Frame: First Month (at Day 1 and Day 15) ]
    For patients enrolled in the phase Ib (dose escalation phase) pharmacokinetic samples (blood) will be collected at Cycle 1 Day 1 and Cycle 1 Day 15. There will be 5 samples per day: pre-infusion, end of infusion, 2 hours, 8 hours and 24 hours after the start of Copanlisib infusion.

  • Area Under the Curve [AUC] for Copanlisib pharmacokinetic [ Time Frame: First Month (at Day 1 and Day 15) ]
    For patients enrolled in the phase Ib (dose escalation phase) pharmacokinetic samples (blood) will be collected at Cycle 1 Day 1 and Cycle 1 Day 15. There will be 5 samples per day: pre-infusion, end of infusion, 2 hours, 8 hours and 24 hours after the start of Copanlisib infusion.

  • Mutational profile of circulating tumoral DNA (ctDNA) [ Time Frame: through the study duration: baseline, C1D1, C1D15, 8 weeks, disease progression ]
    For patients enrolled in the phase II (dose escalation phase) blood samples will be collected at baseline, C1D1, C1D15, 8 weeks, Disease progression or end of treatment whichever comes first.


Estimated Enrollment: 32
Study Start Date: June 2016
Estimated Study Completion Date: June 2020
Estimated Primary Completion Date: November 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Copanlisib + Cetuximab
All patients will be treated by Copanlisib in association with Cetuximab.
Drug: Copanlisib
Copanlisib will be given at Day 1, Day 8 and Day 15 (1 cycle = 28 days), administered intravenously over 60 minutes, in association with Cetuximab.
Other Name: BAY 80-6946
Drug: Cetuximab
Cetuximab will be given weekly at Day 1, Day 8, Day 15 and Day 22 (1 cycle = 28 days), administered intravenously over 120 minutes (Cycle 1 Day 1) or 60 minutes (subsequent infusions), in association with Copanlisib.
Other Name: Erbitux

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients with R/M HNSCC (oropharynx, oral cavity, hypopharynx and larynx), histologically or cytologically confirmed, not amenable to curative treatment with surgery and/or chemotherapy and/or radiotherapy (Stage III/IV)
  2. Adult men and women ≥ 18 years
  3. Patients with ECOG performance status 0 - 2 (ECOG: Eastern Cooperative Oncology Group)
  4. Patients with tumor harboring a PI3K mutation/amplification and/or a PTEN loss
  5. Patients with a radiologic documented progression or relapse after cetuximab therapy (patients could have either received combination platinum doublet with cetuximab or cetuximab after platinum doublet)
  6. Patients with prior platinum based therapy, unless contraindicated
  7. Patients with at least one measurable lesion assessed by Magnetic Resonance Imaging (MRI) or a computerized tomography scanner (CT-scan) according to RECIST 1.1. Patients must have clinically and/or radiographically documented measurable disease. At least one site of disease must be unidimensionally measurable as follows

    • CT-scan, physical exam ≥ 10 mm
    • Lymph node short axis ≥ 15 mm Tumor measurements must be performed within 28 days prior to starting study drug.
  8. Women of childbearing potential and men must agree to use adequate contraception when sexually active. This applies since signing of the informed consent form and up to 12 months (for women of child bearing potential) and 6 months (for fertile men) after the last study drug administration (Copanlisib). Highly effective contraception methods are detailed in section 7.2.
  9. Women of childbearing age or sexually active female patients with reproductive potential must have a negative pregnancy test (serum or urine within the 7 days prior to starting study drug).
  10. Provision of signed and dated, written informed consent prior to any study specific procedures, sampling and analyses
  11. Patients with social insurance coverage
  12. Glomerular filtration rate (GFR) ≥ 40 mL/min/1.73 m² according to the Modification of Diet in Renal Disease (MDRD) abbreviated formula (within 7 days prior to starting study drug). If not on target, this evaluation may be repeated once after at least 24 hours either according to the MDRD abbreviated formula or by 24 hour sampling. If the later result is within acceptable range, it may be used to fulfill the inclusion criteria instead.

Exclusion Criteria:

  1. Patients previously treated with PI3K and/or mTOR inhibitors
  2. Patients with anticancer therapy (radiotherapy, immunotherapy, chemotherapy, etc.) within 28 days or investigational treatment within 28 days prior to the initiation of study drug treatment, unless evidence of progression since last treatment
  3. Patients currently using other approved or investigational anti-neoplasic agent
  4. Patients with uncontrolled arterial hypertension despite optimal medical management, Congestive heart failure > New York Heart Association (NYHA) class 2, Unstable angina (angina symptoms at rest), new-onset angina (begun within the last 3 months). Myocardial infarction less than 6 months before start of test drug No active cardiac disease including any of the following: left ventricular ejection fraction (LVEF) < 50% as determined by Multiple Gated Acquisition (MUGA) scan or echocardiogram (ECHO) and QTc > 470 ms on screening ECG
  5. Patients with uncontrolled diabetes mellitus (patients with controlled Type I or II diabetes mellitus will be eligible but only into the phase II of the study and only if fasting HbA1c ≤ 8.5% at screening)
  6. Patients with a history of Human Immunodeficiency Virus (HIV) Hepatitis B (HBV) or hepatitis C (HCV) infection. All patients must be screened for HIV, HBV and HCV up to 28 days prior to first dosing using the routine virus laboratorial panel. Patients who are positive for HBs Ag or HBc Ab will be eligible if they are negative for HBV-DNA. Patients who are positive for anti-HCV antibody will be eligible if they are negative for HCV-RNA
  7. Patients with active uncontrolled or symptomatic central nervous system (CNS) metastases. Patients are eligible if their disease is controlled at least 30 days on corticosteroids prior to starting study drug.
  8. Patients with major surgery within 28 days, or open biopsy within 7 days, prior to starting study drug. Patients must have recovered from major side effects of the surgery.
  9. Patients receiving any medications or substances that are inhibitors or inducers of CYP3A4 are ineligible. Copanlisib is primarily metabolized by CYP3A4. Therefore concomitant use of strong inhibitors of CyP3A4 (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir, indinavir, nelfinavir and saquinavir), and inducers of CYP3A (e.g. rifampin, phenytoin, carbamazepine, phenobarbital, st. John's Wort) are not permitted from Day -14 of Cycle 1 until the Safety follow up visit.
  10. Patients with altered hematopoietic or organ function, as indicated by the following criteria (assessed within -7 days prior the first dosing):

    • Absolute granulocytes < 1.0 ×109/L
    • Platelets < 75 x 109/L
    • ALAT/ASAT > 2.5 x ULN in the absence of or > 5x ULN in the presence of liver metastases
    • Bilirubin > 1.5 x ULN (except Gilbert Syndrome : < 3.0 mg/dL)
    • Creatinine clearance < 60 mL/min (measured or calculated by Cockcroft and Gault formula) or serum creatinine > 1.0 x ULN
    • Lipase > 1.5 x ULN
    • INR and PTT > 1.5 x ULN
  11. Patients with a history of hypersensitivity to other monoclonal antibodies or to the active or inactive excipients of study drug
  12. Known drug or alcohol abuse
  13. Known or underlying medical condition that, in the investigator's opinion, would make the administration of study drug hazardous to the patient or obscure the interpretation of toxicity determination or adverse events
  14. History of uncontrolled seizures, seizure disorder requiring medication, central nervous system disorders or psychiatric disability judged by the investigator to be clinically significant, precluding informed consent, or interfering with compliance of oral drug intake
  15. Unwillingness to give written informed consent, unwillingness to participate, or inability to comply with the protocol for the duration of the study
  16. Individuals deprived of liberty or placed under the authority of a tutor
  17. Previous or concurrent history of malignancies within 5 years prior to study treatment except for curatively treated:

    • Cervical carcinoma in situ
    • Non-melanoma skin cancer
    • Superficial bladder cancer (Ta [non-invasive tumor], Tis [carcinoma in situ] and T1 [tumor invades lamina propria])
    • Localized prostate cancer
  18. Patients with evidence or history of bleeding diathesis. Any hemorrhage or bleeding event ≥ CTCAE Grade 3 within 4 weeks prior to the start of study medication
  19. Proteinuria of ≥ CTCAE Grade 3 as assessed by a 24h protein quantification or estimated by urine protein-creatinine ratio > 3.5 on a random urine sample
  20. History or concurrent condition of interstitial lung disease of any severity and/or severely impaired lung function (as judged by the investigator)
  21. Concurrent diagnosis of pheochromocytoma
  22. Pregnant or breast-feeding patients. Women of childbearing potential must have a serum pregnancy test performed a maximum of 7 days before start of treatment, and a negative result must be documented before start of treatment.
  23. Unresolved toxicity higher than CTCAE Grade 1 attributed to any prior therapy/procedure, excluding alopecia
  24. Ongoing immunosuppressive therapy
  25. Blood or platelets transfusion less than 7 days before starting treatment
  26. Myeloid growth factors within 14 days prior to treatment
  27. Systemic continuous corticosteroid therapy at a daily dose higher than 15 mg prednisone or equivalent is not allowed. Previous corticosteroid therapy must be stopped or reduced to the allowed dose 7 days before performing the screening CT scan/MRI, whichever is performed first, and again prior to the first study drug administration. If a patient is on chronic corticosteroid therapy, corticosteroids should be de-escalated to the maximum allowed dose after the patient has signed the IC. Patients may be using topical or inhaled corticosteroids.
  28. History of having received an allogeneic bone marrow or organ transplant
  29. Anti-arrhythmic therapy (beta blockers or digoxin are permitted)
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02822482


Contacts
Contact: Jessy DELAYE +33 (0)1 44 23 55 77 j-delaye@unicancer.fr
Contact: Isabelle Jallut +33 (0)1 44 23 04 11

Locations
France
Institut de Cancérologie de l'Ouest Recruiting
Angers, France, 49933
Contact: Frédéric Rolland, MD       frederic.rolland@ico.unicancer.fr   
Contact: Olivier Capitain, MD       olivier.capitain@ico.unicancer.fr   
Centre Georges François Leclerc Not yet recruiting
Dijon, France, 21079
Contact: Nicolas Isambert, MD       nisambert@cgfl.fr   
Centre Oscar Lambret Not yet recruiting
Lille, France, 59020
Contact: Nuria Kotecki, MD       n-kotecki@o-lambret.fr   
Centre Léon Bérard Not yet recruiting
Lyon, France, 69437
Contact: Jérôme Fayette, MD       jerome.fayette@lyon.unicancer.fr   
Institut de Cancérologie de Lorraine Not yet recruiting
Nancy, France, 54511
Contact: Marie-Christine Kaminsky, MD       mc.kaminsky@nancy.unicancer.fr   
Centre Antoine Lacassagne Not yet recruiting
Nice, France, 06189
Contact: Esma Saada-Bouzid, MD       esma.saada-bouzid@nice.unicancer.fr   
Institut Curie Recruiting
Paris, France, 75005
Contact: Christophe Le Tourneau, MD       christophe.letourneau@curie.fr   
Contact: Marie Alt, MD       marie.alt@curie.fr   
Sponsors and Collaborators
UNICANCER
  More Information

Responsible Party: UNICANCER
ClinicalTrials.gov Identifier: NCT02822482     History of Changes
Other Study ID Numbers: UC-0130/1507
2015-004340-19 ( EudraCT Number )
First Submitted: June 16, 2016
First Posted: July 4, 2016
Last Update Posted: March 30, 2017
Last Verified: March 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: Individual Participant Data will not be shared at an individual level. Those data will be part of the study database including all enrolled patients.

Additional relevant MeSH terms:
Carcinoma
Carcinoma, Squamous Cell
Head and Neck Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Squamous Cell
Neoplasms by Site
Cetuximab
Antineoplastic Agents